Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

L.A. McKeown

February 14, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

Todd Neale

December 27, 2021

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

L.A. McKeown

May 21, 2021

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

Yael L. Maxwell

May 12, 2020

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

L.A. McKeown

February 24, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

Advertisement

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

CMS Announces Negotiated Medicare Prices for First 10 Drugs

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Vast Majority of HFrEF Patients Eligible for Vericiguat

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

FDA Approves Two Additional Indications for Rivaroxaban in Children

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

FDA Approves Two Generic Versions of Apixaban

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content